Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
OTCMKTS:SKVI

Skinvisible Q2 2026 Earnings Report

$0.18 +0.00 (+0.56%)
As of 11:38 AM Eastern
ProfileEarnings History

Skinvisible EPS Results

Actual EPS
-$0.05
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Skinvisible Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Skinvisible Announcement Details

Quarter
Q2 2026
Date
8/13/2026
Time
During Market Hours
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Skinvisible Earnings Headlines

SKINVISIBLE INC by Skinvisible, Inc. Insider Trading Activity | OTC:SKVI | Benzinga
May 17, 2026  |  benzinga.comhttps://www.benzinga.com/quote/SKVI/insider-trades
Skinvisible Inc.
May 11, 2026  |  marketwatch.comhttps://www.marketwatch.com/investing/stock/SKVI/financials
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.tc pixel
August 14 at 1:00 AM  |  Stansberry Research (Ad)
Skinvisible Stock Price History
October 9, 2025  |  investing.comhttps://www.investing.com/equities/skinvisible-inc-historical-data
Ovation Science and Skinvisible Pharmaceuticals Enhance Their Strategic Partnership in the Obesity Market with Innovative Cannabinoid Delivery Technology with New Developments ...
September 19, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/OVATF/pressreleases/34883721/ovation-science-and-skinvisible-pharmaceuticals-enhance-their-strategic-partnership-in-the-obesity-market-with-innovative-cannabinoid-delivery-technology-with-new-developments-and-patent-protection/
Skinvisible Delays 10-K Filing Due to Compilation Issues
March 31, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/skinvisible-delays-10-k-filing-due-to-compilation-issues?utm_source=marketbeat.com&utm_medium=referral
See More Skinvisible Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Skinvisible? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Skinvisible and other key companies, straight to your email.

About Skinvisible

Skinvisible (OTCMKTS:SKVI), Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women's health, pain management, and other markets. The company's flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically applied skin care products. It also develops and licenses prescription and over-the-counter products to pharmaceutical and consumer goods companies; assists pharmaceutical clients in the early development of the formulations; and provides solutions to pharmaceutical companies by reformulating their products coming off patent with a new Invisicare patent, and new product benefits and line extensions. The company was formerly known as Microbial Solutions, Inc. and changed its name to Skinvisible, Inc. in February 1999. Skinvisible, Inc. was incorporated in 1998 and is based in Las Vegas, Nevada.

View Skinvisible Profile
Earnings Tools